Robert Rifkin, MD, Rocky Mountain Cancer Center, Denver, Colorado, discusses results from the TOURMALINE-MM2 trial which compared ixazomib, lenalidomide, and dexamethasone (IRd) versus placebo-Rd for transplant-ineligible patients with newly diagnosed MM.
These results were presented at the virtual 62nd ASH Annual Meeting and Exposition.